Opko Executive Investment Will Buy 12 Months; 2008 Losses Decline | GenomeWeb

Opko Health expects to be able to fund its operations into early 2010 after an investment group controlled by the company's chairman and CEO agreed to by $20 million worth of the ophthalmic drug and device shop's stock, according to a US Securities and Exchange Commission filing published this week.

Also in the filing, Opko disclosed its financial results for 2008 and provided an update on a legal dispute in which it has been charged with illegally interfering with the business of a rival.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.